journal article·2024-02-07Open access

Machine Learning-Assisted Optimization of Drug Combinations in Zeolite-Based Delivery Systems for Melanoma Therapy

Ana Raquel Bertão, Filipe Teixeira, Viktoriya Ivasiv, Pier Parpot, Cristina Almeida-Aguiar, António M. Fonseca, Manuel Bañobre-López, Fátima Baltazar, Isabel C. Neves

Abstract

High Resolution Image Download MS PowerPoint Slide Two independent artificial neural network (ANN) models were used to determine the optimal drug combination of zeolite-based delivery systems (ZDS) for cancer therapy. The systems were based on the NaY zeolite using silver (Ag + ) and 5-fluorouracil (5-FU) as antimicrobial and antineoplastic agents. Different ZDS samples were prepared, and their characterization indicates the successful incorporation of both pharmacologically active species without any relevant changes to the zeolite structure. Silver acts as a counterion of the negative framework, and 5-FU retains its molecular integrity. The data from the A375 cell viability assays, involving ZDS samples (solid phase), 5-FU, and Ag + aqueous solutions (liquid phase), were used to train two independent machine learning (ML) models. Both models exhibited a high level of accuracy in predicting the experimental cell viability results, allowing the development of a novel protocol for virtual cell viability assays. The findings suggest that the incorporation of both Ag and 5-FU into the zeolite structure significantly potentiates their anticancer activity when compared to that of the liquid phase. Additionally, two optimal AgY/5-FU@Y ratios were proposed to achieve the best cell viability outcomes. The ZDS also exhibited significant efficacy against Escherichia coli ( E. coli ) and Staphylococcus aureus ( S. aureus ); the predicted combination ratio is also effective against S. aureus, underscoring the potential of this approach as a therapeutic option for cancer-associated bacterial infections.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Spectroscopy Techniques in Biomedical and Chemical Research · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CQUM, Centre of Chemistry, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal

ICVS/3B’s - PT Government Associate Laboratory, University of Minho, 4710-057 Braga/Guimarães, Portugal

Advanced (Magnetic) Theranostic Nanostructures Lab, Nanomedicine Group, International Iberian Nanotechnology Laboratory (INL), Av. Mestre José Veiga, 4715-330 Braga, Portugal

CEB - Centre of Biological Engineering, University of Minho, 4710-057 Braga, Portugal

CBMA - Centre of Molecular and Environmental Biology, University of Minho, 4710-057 Braga, Portugal

Funding

European Regional Development Fund · Funda??o para a Ci?ncia e a Tecnologia

References (50)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1158/2159-8290.CD-21-105910.1158/2159-8290.CD-21-1059 ↗
3. 10.1126/science.abc455210.1126/science.abc4552 ↗
4. 10.1126/science.aah504310.1126/science.aah5043 ↗
5. 10.1038/srep1455410.1038/srep14554 ↗
6. 10.1016/j.heliyon.2021.e0594810.1016/j.heliyon.2021.e05948 ↗
7. 10.3390/cancers1304066910.3390/cancers13040669 ↗
8. 10.1016/j.jconrel.2016.06.01210.1016/j.jconrel.2016.06.012 ↗
9. 10.1016/j.micromeso.2020.11050810.1016/j.micromeso.2020.110508 ↗
10. 10.1016/j.ccr.2018.12.01410.1016/j.ccr.2018.12.014 ↗
11. 10.1039/C7RA01028A10.1039/C7RA01028A ↗
12. 10.1016/j.csbj.2021.07.00310.1016/j.csbj.2021.07.003 ↗
13. 10.1016/j.micromeso.2022.11236210.1016/j.micromeso.2022.112362 ↗
14. 10.1016/j.envres.2019.03.05510.1016/j.envres.2019.03.055 ↗
15. 10.1016/j.ijhydene.2022.05.03810.1016/j.ijhydene.2022.05.038 ↗
16. 10.1016/j.micromeso.2004.09.01810.1016/j.micromeso.2004.09.018 ↗
17. 10.1016/j.mex.2020.10088510.1016/j.mex.2020.100885 ↗
18. 10.1111/jep.1257310.1111/jep.12573 ↗
19. 10.1016/j.hoc.2020.08.01110.1016/j.hoc.2020.08.011 ↗
20. 10.1111/j.1365-2133.2012.10830.x10.1111/j.1365-2133.2012.10830.x ↗
21. 10.1186/s40246-019-0211-910.1186/s40246-019-0211-9 ↗
22. Gandhi M. · 2014 · 29910.1007/978-3-319-04220-6_10 ↗
23. 10.1100/2012/80451810.1100/2012/804518 ↗
24. 10.1016/j.colsurfb.2016.02.04210.1016/j.colsurfb.2016.02.042 ↗
25. 10.1007/s11164-019-03842-z10.1007/s11164-019-03842-z ↗
26. 10.1016/j.colsurfb.2013.07.04210.1016/j.colsurfb.2013.07.042 ↗
27. 10.1021/jp306726610.1021/jp3067266 ↗
28. 10.1038/nprot.2006.17910.1038/nprot.2006.179 ↗
29. 10.1016/j.ymeth.2007.01.00610.1016/j.ymeth.2007.01.006 ↗
30. Pedregosa F. · J. Mach. Learn. Res. · 2011 · 12 · 2825
31. 10.1016/0038-1098(75)90468-810.1016/0038-1098(75)90468-8 ↗
32. Childs K. D. · 1995
33. 10.1021/ac50051a02110.1021/ac50051a021 ↗
34. 10.1016/j.micromeso.2023.11287110.1016/j.micromeso.2023.112871 ↗
35. 10.1021/acs.iecr.1c0173610.1021/acs.iecr.1c01736 ↗
36. 10.1111/j.1365-2672.2007.03673.x10.1111/j.1365-2672.2007.03673.x ↗
37. 10.1007/s12668-013-0085-610.1007/s12668-013-0085-6 ↗
38. 10.3390/ijms1908226910.3390/ijms19082269 ↗
39. 10.1038/nrc107410.1038/nrc1074 ↗
40. 10.1039/C8BM00028J10.1039/C8BM00028J ↗
41. 10.3390/cosmetics901002610.3390/cosmetics9010026 ↗
42. 10.1016/j.micromeso.2013.07.01810.1016/j.micromeso.2013.07.018 ↗
43. 10.1021/acsami.7b1500110.1021/acsami.7b15001 ↗
44. 10.1128/AEM.69.7.4278-4281.200310.1128/AEM.69.7.4278-4281.2003 ↗
45. 10.1016/j.celrep.2022.11162510.1016/j.celrep.2022.111625 ↗
46. 10.1128/microbiolspec.dmih2-0014-201510.1128/microbiolspec.dmih2-0014-2015 ↗
47. 10.1155/2008/84645310.1155/2008/846453 ↗
48. 10.1039/C5RA04960A10.1039/C5RA04960A ↗
49. 10.1016/j.micromeso.2012.05.00610.1016/j.micromeso.2012.05.006 ↗
50. 10.1016/j.apsusc.2015.11.01010.1016/j.apsusc.2015.11.010 ↗